New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
11:28 EDTVNDAVanda Pharmaceuticals reports USPTO notice of patent allowance
Vanda Pharmaceuticals disclosed in a regulatory filing that on June 10 the company received a notice of allowance from the United States Patent and Trademark Office for a patent covering the method of use of HETLIOZ to treat Non-24-Hour Sleep-Wake Disorder. The allowed claims relate to the method of treatment as described in the HETLIOZ label that was approved by the FDA and include claims directed to treatment of the totally blind population that has this disorder. Following the expected issuance of the VAND-0092 patent, Vanda intends to submit the patent for listing in the FDA publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The VAND-0092 patent, when issued, would be expected to expire in 2033, thereby potentially extending the exclusivity protection in the U.S. for method of using HETLIOZ in Non-24 beyond the expiration of the U.S. composition of matter patent for HETLIOZ, which is currently expected to expire in 2022.
News For VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 3, 2015
07:02 EDTVNDAVanda's new four Fanapt patents listed in FDA publication
Subscribe for More Information
July 29, 2015
19:32 EDTVNDAOn The Fly: After Hours Movers
Subscribe for More Information
16:21 EDTVNDAVanda raises FY15 Hetlioz, Fanapt sales to $100M-$115M from $95M-$110M
FY15 revenue consensus is $104.18M. Sees Hetlioz sales $40M-$45M. Raises Fanapt sales to $60M-$70M from $55M-$65M.
16:18 EDTVNDAVanda reports Q2 adjusted EPS (1c), may not compare to two estimates (29c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use